Similar articles

• Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris.

  Thiboutot DM, Willmer J, Sharata H, Halder R, Garrett S. Thiboutot DM, et al. Clin Pharmacokinet. 2007;46(8):697-712. doi: 10.2165/00003088-200746080-00006. Clin Pharmacokinet. 2007. PMID: 17655376 Clinical Trial.
• The sulfone syndrome complicated by pancreatitis and pleural effusion in an adolescent receiving dapsone for treatment of acne vulgaris.

  Corp CC, Ghishan FK. Corp CC, et al. J Pediatr Gastroenterol Nutr. 1998 Jan;26(1):103-5. doi: 10.1097/00005176-199801000-00017. J Pediatr Gastroenterol Nutr. 1998. PMID: 9443128 No abstract available.
• Dapsone 7.5% Gel: A Review in Acne Vulgaris.

  Al-Salama ZT, Deeks ED. Al-Salama ZT, et al. Am J Clin Dermatol. 2017 Feb;18(1):139-145. doi: 10.1007/s40257-016-0242-0. Am J Clin Dermatol. 2017. PMID: 28005194 Review.
• An evaluation of dapsone gel 5% in the treatment of acne vulgaris.

  Pickert A, Raimer S. Pickert A, et al. Expert Opin Pharmacother. 2009 Jun;10(9):1515-21. doi: 10.1517/14656560903002097. Expert Opin Pharmacother. 2009. PMID: 19505219 Review.
• Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.

  Eichenfield LF, Lain T, Frankel EH, Jones TM, Chang-Lin JE, Berk DR, Ruan S, Kaoukhov A. Eichenfield LF, et al. J Drugs Dermatol. 2016 Aug 1;15(8):962-9. J Drugs Dermatol. 2016. PMID: 27537997 Clinical Trial.